title: Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors.
abstract: Bone marrow is a major homing site for circulating epithelial tumor cells. The present study was aimed to assess the proliferative capacity of occult metastatic cells in bone marrow of patients with operable solid tumors especially with regard to their clinical outcome. We obtained bone marrow aspirates from 153 patients with carcinomas of the prostate (n = 46), breast (n = 45), colon (n = 33), and kidney (n = 29). Most of the patients (87%) had primary disease with no clinical signs of overt metastases [tumor-node-metastasis (TNM)-stage UICC (Union Internationale Contre le Cancer) I-III]. After bone marrow was cultured for 21-102 days under special cell culture conditions, viable epithelial cells were detected by cytokeratin staining in 124 patients (81%). The cultured epithelial cells harbored Ki-ras2 mutations and numerical chromosomal aberrations. The highest median number of expanded tumor cells was observed in prostate cancer (2,619 per flask). There was a significant positive correlation between the number of expanded tumor cells and the UICC-stage of the patients (P = 0.03) or the presence of overt metastases (P = 0.04). Moreover, a strong expansion of tumor cells was correlated to an increased rate of cancer-related deaths (P = 0.007) and a reduced survival of the patients (P = 0.006). In conclusion, the majority of cancer patients have viable tumor cells in their bone marrow at primary tumor diagnosis, and the proliferative potential of these cells determines the clinical outcome.
authors.affiliation: Molekulare Onkologie, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Hamburg, Germany.
authors.forename: Oender
authors.initials: O
authors.lastname: Solakoglu
authors.forename: Christine
authors.initials: C
authors.lastname: Maierhofer
authors.forename: Georgia
authors.initials: G
authors.lastname: Lahr
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Breit
authors.forename: Peter
authors.initials: P
authors.lastname: Scheunemann
authors.forename: Isabella
authors.initials: I
authors.lastname: Heumos
authors.forename: Uwe
authors.initials: U
authors.lastname: Pichlmeier
authors.forename: Gunter
authors.initials: G
authors.lastname: Schlimok
authors.forename: Ralph
authors.initials: R
authors.lastname: Oberneder
authors.forename: Manfred W
authors.initials: MW
authors.lastname: Kollermann
authors.forename: Jens
authors.initials: J
authors.lastname: Kollermann
authors.forename: Michael R
authors.initials: MR
authors.lastname: Speicher
authors.forename: Klaus
authors.initials: K
authors.lastname: Pantel
mesh_terms: D001854:Bone Marrow Cells / Q000166:cytology; D001943:Breast Neoplasms / Q000175:diagnosis; D002455:Cell Division; D002467:Cell Nucleus / Q000378:metabolism; D002478:Cells, Cultured; D002869:Chromosome Aberrations; D003110:Colonic Neoplasms / Q000175:diagnosis; D005260:Female; D011905:Genes, ras / Q000235:genetics; D006801:Humans; D017403:In Situ Hybridization; D017404:In Situ Hybridization, Fluorescence; D007680:Kidney Neoplasms / Q000175:diagnosis; D008297:Male; D009154:Mutation; D009362:Neoplasm Metastasis; D009382:Neoplasms, Unknown Primary / Q000175:diagnosis / Q000378:metabolism* / Q000401:mortality; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis; D012878:Skin Neoplasms / Q000378:metabolism*; D013997:Time Factors